Targeting signal transduction in pancreatic cancer treatment.

Targeting signal transduction in pancreatic cancer treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Targeting signal transduction in pancreatic cancer treatment. Abstract Text:

Jen Jen Yeh,Channing J Der,

Pancreatic cancer is a lethal disease with a 5-year survival rate of 4%. The only opportunity for improved survival continues to be complete surgical resection for those with localized disease. Although chemotherapeutic options are limited for the few patients with resectable disease, this problem is even more magnified in the majority (85%) of patients with unresectable or metastastic disease. Therefore, there is an urgent need for improved therapeutic options. The recent success of inhibitors of signal transduction for the treatment of other cancers supports the need to identify and validate aberrant signaling pathways important for pancreatic tumor growth. This review focuses on the validation of specific signaling networks and the present status of inhibitors of these pathways as therapeutic approaches for pancreatic cancer treatment.

Targeting signal transduction in pancreatic cancer treatment. Publishing Authors By Initials

JJ Yeh,CJ Der,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

Targeting signal transduction in pancreatic cancer treatment. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert opinion on therapeutic targets

VOLUME: 11

Page Numbers: 673-94

Journal Abbreviation:

ISSN: 1744-7631

DAY: 3

MONTH: May

YEAR: 2007

Targeting signal transduction in pancreatic cancer treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101127833

Targeting signal transduction in pancreatic cancer treatment. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: physiology

Chemical & Substance for Abstract: Targeting signal transduction in pancreatic cancer treatment. Information

Substance Name: Proto-Oncogene Proteins p21(ras)

Registry Number: EC 3.6.5.2

Grant and Affiliation Information for Targeting signal transduction in pancreatic cancer treatment.

AFFILIATION: University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Division of Surgical Oncology, Chapel Hill, NC 27599, USA. jjyeh@med.unc.edu

Country: England

AGENCY: United States NICHD

GRANT: HD052191

ACRONYM: HD

MEDLINETA: Expert Opin Ther Targets

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Targeting signal transduction in pancreatic cancer treatment Related Publications

• A clinical comparison of bone imaging agents.
• Body mass index, abdominal adiposity, obesity, and cardiovascular reactions to psychological stress in a large community sample.
• Characterization of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases.
• DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
• Explanations for female excess psychosomatic symptoms in adolescence: evidence from a school-based cohort in the West of Scotland.
• Genetic and pharmacologic dissection of ras effector utilization in oncogenesis.
• Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.
• K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
• Ras-driven transformation of human nestin-positive pancreatic epithelial cells.
• Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling.
• Real-Time In Vitro Measurement of Intrinsic and Ras GAP-Mediated GTP Hydrolysis.
• Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
• Targeting signal transduction in pancreatic cancer treatment.
• Tools to study the function of the ras-related, estrogen-regulated growth inhibitor in breast cancer.